SCHEMBL9924873

SCHEMBL9924873

CCCC1CCC2CC(COc3ccc(-c4ccc(OC)c(F)c4F)c(F)c3F)CCC2C1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHA2 P29317 5/20 0.33
KDR P35968 5/20 0.33
EPHB4 P54760 5/20 0.33
SGPL1 O95470 1/20 0.33
S1PR1 P21453 1/20 0.33
SCN9A Q15858 1/20 0.33
PDE4B Q07343 6/20 0.32
ERBB2 P04626 2/20 0.32
FLT1 P17948 2/20 0.32
PDE4A P27815 2/20 0.32
PDE4C Q08493 2/20 0.32
PDE4D Q08499 2/20 0.32
HTR2A P28223 2/20 0.32
HTR2C P28335 2/20 0.32
HTR2B P41595 2/20 0.32
KCNH2 Q12809 2/20 0.31
CYP2D6 P10635 1/20 0.31
GRIN2B Q13224 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31
FPR2 P25090 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9925151 0.95 PDE4B (0.33) EPHA2KDREPHB4SGPL1S1PR1
SCHEMBL9924752 0.95 SCN9A (0.35) EPHA2KDREPHB4SGPL1S1PR1
SCHEMBL9896544 0.93 SCN9A (0.34) SCN9AHTR2AHTR2CHTR2BGRIN2B
SCHEMBL9925138 0.91 SCN9A (0.33) SCN9AHTR2AHTR2CHTR2B
SCHEMBL9924821 0.90 PDE4B (0.35) EPHA2KDREPHB4SGPL1S1PR1
SCHEMBL9924783 0.90 SCN9A (0.36) EPHA2KDREPHB4SGPL1S1PR1
SCHEMBL9924879 0.89 PDE10A (0.33) SCN9AHTR2AHTR2CHTR2B
SCHEMBL9924874 0.89 SCN9A (0.32) SCN9AHTR2AHTR2CHTR2B
SCHEMBL12032407 0.89 HTR2A (0.34) SCN9AHTR2AHTR2CHTR2BKCNH2
SCHEMBL9924881 0.88 CTSL (0.34) SCN9AHTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468707-B1 DECAHYDRONAPHTHALENE COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS CONTAINING THE COMPOUNDS, AND LIQUID CRYSTAL DISPLAY DEVICES CONTAINING THE LIQUID CRYSTAL COMPOSITIONS JNC CORP (JP) 2017-08-02 EP disclosed
US-8465674-B2 Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition JNC CORPORATION (JP) 2013-06-18 US disclosed
US-8465674-B2 Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition JNC CORPORATION (JP) 2013-06-18 US disclosed
EP-2468707-A1 DECAHYDRONAPHTHALENE COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS CONTAINING THE COMPOUNDS, AND LIQUID CRYSTAL DISPLAY ELEMENTS CONTAINING THE LIQUID CRYSTAL COMPOSITIONS JNC Corporation (JP) 2012-06-27 EP disclosed
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION JNC PETROCHEMICAL CORPORATION (JP) 2012-06-14 US disclosed
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION JNC PETROCHEMICAL CORPORATION (JP) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION DCUN1D2, OCIAD1, CPNE4 EPHA2 1615/4885KDR 1097/4885EPHB4 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.